Crick — Clinical Intelligence Platform

Not applicableStudy completedNCT01505205

What this trial is testing

Study on the Evolution of Genes Mutation Related With Gastrointestinal Stromal Tumors

Who this might be right for

Full Gene Sequences of c-KIT、PDGFRA and DOG1 Are Analyzed With the Screening-sequencing ApproachInvestigate the Characteristics and Variations Associated With the Different Gene Mutations of c-KIT、PDGFRA and DOG1 in GIST Patients

Guangxi Medical University 60

Results for “C-KIT Mutation”

AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

The Significance of Blood-tryptase and c-Kit Mutation in Insect Venom Immunotherapy

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation

A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread

Molecular Mechanisms and Diagnosis of Mastocytosis

Study on the Evolution of Genes Mutation Related With Gastrointestinal Stromal Tumors

Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation

POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy

Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment

Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma

Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation